Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Patent-Blocking Strategies May Stunt Research

This article was originally published in Scrip

Executive Summary

The patent-blocking strategies being used by some international advocacy groups to promote access to cheaper drugs in developing nations can be seen to be good thing; however, it is important that issues concerning the availability of the drug and the pricing of the drug are kept separate. If there is pressure on patent courts to decide against awarding a patent to a drug company because there is a desire to have the drug at a low price, this results in a conflict of interests and will fundamentally invalidate the patent system. If such situations occur they could stunt vital drug research programs, writes patent attorney Adrian Tombling.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC029905

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst

Cancel